The method of synthesis according to claim 4, characterized in that: in the step (1), the alkali-water-organic solvent is any one of a triethylamine/water/acetonitrile system, an N, N-diisopropylethylamine/water/N, N-dimethylformamide and an N, N-diisopropylethylamine/water/N, N-dimethylacetamide system
As Ozempic reduces appetite and promotes weight reduction, the body loses insulating adipose tissue and basal metabolic rate may decline, potentially leading to increased cold sensitivity
But semaglutide is not insulin
1 In adults with obesity, along with diet and exercise, A well-studied safety profile for adults with obesity: Pooled safety data from 2 weight-management clinical trials evaluating Wegovy HD 7.2 mg 1 Wegovy HD (semaglutide) injection 7.2 mg had a safety profile consistent with Wegovy 2.4 mg 1,3 5% of patients with Wegovy HD 7.2 mg pen, 5% of patients with Wegovy 2.4 mg pen, and 2% of patients with placebo permanently discontinued as a result of adverse reactions 1 The most common adverse reactions leading to discontinuation were gastrointestinal disorders: 3% of patients with Wegovy HD 7.2 mg pen, 3% of patients with Wegovy 2.4 mg pen, and 0.3% of patients with placebo 1 Includes allodynia, burning sensation, dysesthesia, hyperesthesia, hyperpathia, pain of skin, paresthesia, sensitive skin, skin burning sensation, skin discomfort, and skin sensitization
Though not every anti-diabetic medicine is beneficial for weight reduction in non-diabetics, GLP-1-RAs, particularly semaglutide, stand out for their pleiotropic effects in this regard [7, 9, 14, 15]
